Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.17 +0.6%	$3.95	$1.42 ▼ $5.98	$460.15M	0.88	1.07 million shs	1.90 million shs
CLLS Cellectis	$1.38 +0.7%	$1.48	$1.10 ▼ $2.43	$77.82M	2.92	143,339 shs	36,065 shs
CMPS COMPASS Pathways	$4.80 +7.1%	$4.06	$2.49 ▼ $8.54	$449.10M	2.25	920,182 shs	3.06 million shs
CMPX Compass Therapeutics	$2.38 +8.7%	$2.05	$0.77 ▼ $4.08	$329.11M	1.41	952,958 shs	765,396 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	-4.79%	+48.14%	+40.49%	+516,999,900.00%
CLLS Cellectis	0.00%	+0.97%	-10.39%	+6.15%	-31.51%
CMPS COMPASS Pathways	0.00%	+6.19%	+3.90%	+54.84%	-25.35%
CMPX Compass Therapeutics	0.00%	-1.24%	+13.33%	+3.03%	+112.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.6656 of 5 stars	3.6	1.0	4.0	1.7	0.6
CLLS Cellectis	3.4145 of 5 stars	3.5	5.0	2.3	2.5	0.6
CMPS COMPASS Pathways	2.1436 of 5 stars	3.5	3.0	1.3	0.8	0.6
CMPX Compass Therapeutics	3.7141 of 5 stars	4.6	1.0	3.3	5.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$18.60	259.77% Upside
CLLS Cellectis	3.00	Buy	$4.00	189.86% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	292.36% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	451.47% Upside

Current Analyst Ratings Breakdown

Latest CLLS, CMPS, ATYR, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,000.57	N/A	N/A	$0.83 per share	6.23
CLLS Cellectis	$49.22M	1.56	N/A	N/A	$2.36 per share	0.58
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
CMPX Compass Therapeutics	$850K	387.18	N/A	N/A	$0.91 per share	2.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)

Latest CLLS, CMPS, ATYR, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	7.79	7.79
CLLS Cellectis	0.44	1.67	1.67
CMPS COMPASS Pathways	0.11	10.18	10.18
CMPX Compass Therapeutics	N/A	8.33	8.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
CLLS Cellectis	63.90%
CMPS COMPASS Pathways	46.19%
CMPX Compass Therapeutics	68.43%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
CLLS Cellectis	16.41%
CMPS COMPASS Pathways	3.93%
CMPX Compass Therapeutics	29.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable

CLLS, CMPS, ATYR, and CMPX Headlines

Recent News About These Companies

Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $13.13

June 19 at 1:47 AM | americanbankingnews.com

SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

June 16, 2025 | marketbeat.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of "Buy" by Analysts

June 16, 2025 | marketbeat.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC

June 15, 2025 | marketbeat.com

Head-To-Head Survey: Scilex (NASDAQ:SCLX) & Compass Therapeutics (NASDAQ:CMPX)

June 13, 2025 | americanbankingnews.com

Insider Buying: Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Buys 10,000 Shares of Stock

May 29, 2025 | marketbeat.com

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) CEO Thomas J. Schuetz Purchases 10,000 Shares

May 28, 2025 | insidertrades.com

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Buy" from Brokerages

May 24, 2025 | marketbeat.com

Tang Capital Management LLC Has $8.56 Million Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

May 20, 2025 | marketbeat.com

Stifel Nicolaus Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

May 11, 2025 | theglobeandmail.com

Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 5.62%

May 10, 2025 | aaii.com

Compass Therapeutics price target lowered to $10 from $12 at Guggenheim

May 9, 2025 | msn.com

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 8, 2025 | globenewswire.com

Compass Therapeutics to Participate in Upcoming May Investor Events

May 6, 2025 | globenewswire.com

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

April 28, 2025 | globenewswire.com

2 Penny stocks to buy in May 2025

April 27, 2025 | finbold.com

Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 6.65%

April 26, 2025 | aaii.com

Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer

April 23, 2025 | nasdaq.com

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX) and UnitedHealth (UNH)

April 23, 2025 | markets.businessinsider.com

Compass Therapeutics announces first patient dosed in IST evaluating tovecimig

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, CMPS, ATYR, and CMPX Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.17 +0.03 (+0.58%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.19 +0.02 (+0.39%)

As of 06/18/2025 07:55 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Cellectis NASDAQ:CLLS

$1.38 +0.01 (+0.73%)

Closing price 06/18/2025 03:57 PM Eastern

Extended Trading

$1.42 +0.04 (+2.54%)

As of 06/18/2025 07:51 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

COMPASS Pathways NASDAQ:CMPS

$4.80 +0.32 (+7.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.96 +0.17 (+3.44%)

As of 06/18/2025 07:52 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Compass Therapeutics NASDAQ:CMPX

$2.38 +0.19 (+8.68%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.43 +0.05 (+2.10%)

As of 06/18/2025 06:49 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time